Previous studies illustrated that peroxisome proliferative activated receptor alpha (PPAR-α) agonists such as fenofibrate, gemfibrozil and ciprofibrate could attenuate the inflammatory reactions in MS. The gene discussed is PPARA; the disease is myeloid sarcoma.